Association of BRCA Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With BRCA1 and BRCA2 Mutations.
暂无分享,去创建一个
Hee Jung Shin | Joo Hee Cha | Eun Young Chae | Su Min Ha | Woo Jung Choi | Hak Hee Kim | H. Kim | S. Ha | J. Cha | W. Choi | E. Y. Chae | H. J. Shin
[1] Ellen Warner,et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination , 2004, JAMA.
[2] C. Kuhl,et al. Mammographic, US, and MR imaging phenotypes of familial breast cancer. , 2008, Radiology.
[3] C. Wells,et al. Correlation between ultrasound characteristics, mammographic findings and histological grade in patients with invasive ductal carcinoma of the breast. , 2000, Clinical radiology.
[4] T. Uematsu,et al. Triple-negative breast cancer: correlation between MR imaging and pathologic findings. , 2009, Radiology.
[5] J. C. Marcus,et al. Sonographic appearance of invasive ductal carcinoma of the breast according to histologic grade. , 2012, AJR. American journal of roentgenology.
[6] J. Lee,et al. Association between BRCA Mutation Status, Pathological Findings, and Magnetic Resonance Imaging Features in Patients with Breast Cancer at Risk for the Mutation , 2013, Journal of breast cancer.
[7] Magnetic Resonance Imaging of Breast Cancer Patients with BRCA Mutation , 2013 .
[8] Mads Thomassen,et al. Classifications within Molecular Subtypes Enables Identification of BRCA1/BRCA2 Mutation Carriers by RNA Tumor Profiling , 2013, PloS one.
[9] D Krebs,et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. , 2000, Radiology.
[10] R. Fimmers,et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Christopher I Amos,et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. J. van de Vijver,et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] D. Easton,et al. Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.
[14] Fiona J Gilbert,et al. Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features. , 2009, Radiology.
[15] Harry J de Koning,et al. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] D. Visscher,et al. Centrally Necrotizing Carcinomas of the Breast: A Distinct Histologic Subtype With Aggressive Clinical Behavior , 2001, The American journal of surgical pathology.
[17] D B Plewes,et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Julian Peto,et al. Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.
[19] S. Narod,et al. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.
[20] Jeong Eon Lee,et al. Characteristics of double heterozygosity for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients , 2011, Breast Cancer Research and Treatment.
[21] Bruce L Daniel,et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. , 2006, JAMA.
[22] A R Padhani,et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS) , 2005, The Lancet.
[23] M. Yaffe,et al. American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007 .
[24] S. Heywang-Köbrunner,et al. Multicenter Comparative Multimodality Surveillance of Women at Genetic-Familial High Risk for Breast Cancer (HIBCRIT Study): Interim Results , 2008 .
[25] R. Mann,et al. Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI , 2008, European Radiology.
[26] H. D. de Koning,et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. , 2004, The New England journal of medicine.
[27] Won Hwa Kim,et al. Location of Triple-Negative Breast Cancers: Comparison with Estrogen Receptor-Positive Breast Cancers on MR Imaging , 2015, PloS one.
[28] A. Bowcock,et al. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. , 1997, The New England journal of medicine.
[29] Shuangqing Liu,et al. Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis , 2018, Front. Pharmacol..
[30] Theo van der Kwast,et al. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false‐negative mammography , 2002, International journal of cancer.
[31] Ian O Ellis,et al. Basal-like breast cancer: a critical review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.